Month: November 2024

Taseko to Release Third Quarter 2024 Results

VANCOUVER, British Columbia, Nov. 01, 2024 (GLOBE NEWSWIRE) — Taseko Mines Limited (TSX: TKO; NYSE American: TGB; LSE: TKO) (the “Company”) will release its third quarter 2024 financial results after market close on Wednesday, November 6, 2024. The Company will host a telephone conference call and live webcast on Thursday, November 7, 2024, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific) to discuss these results. After opening remarks by management, there will be a question-and-answer session open to analysts and investors. Participants can join by conference call dial-in or webcast: Conference Call Dial-In Participants can dial in to the conference call; however, pre-registration is required To register, visit https://bit.ly/TasekoQ32024_Dial-in Once registered, an email will be sent, including dial-in details and...

Continue reading

Conference Call – 4th Quarter 2024 Results

VANCOUVER, British Columbia, Nov. 01, 2024 (GLOBE NEWSWIRE) — Rogers Sugar Inc. (RSI) will be holding a conference call to discuss their 2024 fourth quarter results on Thursday, November 28, 2024, at 8h00 (Eastern Time). The conference call will be chaired by Mr. Michael Walton, Chief Executive Officer and Mr. Jean-Sébastien Couillard, Chief Financial Officer. If you wish to participate, please dial 1-800-717-1738. A recording of the conference call will be accessible shortly after the conference, by dialing 1-888-660-6264, access code 67841#. This recording will be available until December 28, 2024. The discussion along with a presentation will be accessible through a webcast at the following address: https://onlinexperiences.com/Launch/QReg/ShowUUID=F7BFF0AB-4F01-4204-8380-F3CB4E711537&LangLocaleID=1033 For further information: Jean-Sébastien...

Continue reading

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-‘749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscience Data show TEV-‘749 drug delivery technology resulted in no occurrence of Post-Injection Delirium/Sedation Syndrome (PDSS) events to date Real-world analyses of UZEDY (risperidone) subcutaneous long-acting injectable reveal high adherence rates and utilization in adults with schizophrenia who have barriers to treatment TEL AVIV, Israel & PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new, positive data on social functioning and quality of life from the Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749...

Continue reading

Liberty Northwest Bancorp, Inc. Reports Third Quarter 2024 Earnings

2024 Third Quarter Financial Highlights: Total assets were $183.7 million at quarter end. Net interest income of $1.01 million for the third quarter. Net interest margin of 2.37% for the third quarter. Total deposits increased 2% to $146.4 million at September 30, 2024, compared to $143.1 million a year ago. Net loans increased 1% to $140.0 million at September 30, 2024, compared to $139.2 million a year ago. Asset quality remains pristine. Non-interest bearing demand deposits represent 27% of total deposits. Tangible book value per share was $7.67 at quarter end. POULSBO, Wash., Nov. 01, 2024 (GLOBE NEWSWIRE) — Liberty Northwest Bancorp, Inc. (OTCQX: LBNW) (the “Company”) and its wholly-owned subsidiary Liberty Bank today announced net income of $25 thousand for the third quarter ended September 30, 2024, compared to $7 thousand...

Continue reading

U.S. Global Investors Announces First Quarter of Fiscal 2025 Webcast

San Antonio, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) — U.S. Global Investors, Inc. (Nasdaq: GROW) will host a webcast on Friday, November 8, 2024, at 7:30 a.m. Central time to discuss the company’s results for the first quarter of fiscal year 2025. ­Financial data for the quarter will be released prior to the webcast. Frank Holmes, Chief Executive Officer and Chief Investment Officer; Lisa Callicotte, Chief Financial Officer; and Holly Schoenfeldt, Director of Marketing, will participate in the webcast. Click here to register for the webcast. #### About U.S. Global Investors, Inc. The story of U.S. Global Investors goes back more than 50 years when it began as an investment club. Today, U.S. Global Investors, Inc. (www.usfunds.com) is a registered investment adviser that focuses on niche markets around the world. Headquartered in San...

Continue reading

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th

HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexalin’s solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries—conditions that affect millions but have limited effective treatments—positioning Nexalin as an emerging leader in a market poised for substantial growth, projected to reach $537...

Continue reading

CryptoBlox Signs Amended & Restated Share Purchase Agreement to Acquire Blockchain Fintech

Cryptoblox to Complete its Diversified Blockchain Strategy with Strategic Acquisition Vancouver, B.C., Nov. 01, 2024 (GLOBE NEWSWIRE) — CryptoBlox Technologies Inc. (the “Company” or “CryptoBlox”) (CSE: BLOX) is pleased to announce that it has signed a binding amended and restated share purchase agreement (the “Amended Agreement”), dated October 31, 2024, to acquire 100% of Blockchain Fintech Unipessoal LDA (“Blockchain Fintech”), a Portuguese corporation that develops blockchain-based financial technologies. The Amended Agreement revises the terms of the acquisition originally announced on March 5, 2024. “The Company is extremely pleased to secure this very strategic acquisition which, upon closing, will complete the final division of our Diversified Blockchain Ecosystem Strategy,” stated Akshay Sood, CEO of CryptoBlox. “We have...

Continue reading

Helport AI Reports Fiscal Full Year 2024 Financial Results

FY 2024 Revenue up 132% to $29.6 Million Year over Year Net Income up 53% to $7.4 Million Year over Year Completed Merger and Began Trading as a Public Company on Nasdaq Under Ticker Symbol “HPAI” on August 5, 2024 Management to Host Business Update Conference Call on Wednesday, November 6, 2024 at 5:30 pm ET SINGAPORE and SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) — Helport AI Limited (NASDAQ: HPAI) (“Helport AI” or the “Company”), an AI technology company serving enterprise clients with intelligent software, services and solutions, today announced financial results for its fiscal full year ended June 30, 2024. Helport AI Highlights: A pioneering AI technology company dedicated to empowering enterprises with intelligent software, services and solutions, aimed at accelerating sales growth, driving operational excellence and reducing...

Continue reading

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference’s partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent clinical progress, including data from its combination study involving Ozempic, a GLP-1 agonist. The BIO-Europe conference provides a prestigious platform for Tiziana to highlight its strategic advancements to the biopharma community, as well as to expand its partnerships aimed...

Continue reading

Seanergy Maritime Releases its 2023 Environmental, Social and Governance Report

GLYFADA, Greece, Nov. 01, 2024 (GLOBE NEWSWIRE) — Seanergy Maritime Holdings Corp. (the “Company” or “Seanergy”) (NASDAQ: SHIP) announced today the release of its Environmental, Social and Governance Report (the “ESG Report”), for the year ended December 31, 2023. The ESG Report outlines Seanergy’s strategy and commitments related to the ESG pillars and reflects on the Company’s performance through sustainability-related Key Performance Indicators. The ESG Report is aligned with the Global Reporting Initiative (GRI 2021) Standards and follows the Sustainability Accounting Standards Board (SASB) for Marine Transportation. Specific GRI disclosures and SASB indicators have received limited level of assurance from CSE North America. The ESG Report is available on Seanergy’s website at https://www.seanergymaritime.com/en/sustainability. About...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.